Archiv: National Institute for Communicable Diseases (BSL-4 laboratory) / South Africa


09.02.2021 - 20:53 [ CNN ]

Why bad news for AstraZeneca’s vaccine is a roadblock on the way out of the pandemic

The study from South Africa suggested that two doses of the AstraZeneca vaccine provided „substantially reduced“ protection against mild to moderate Covid-19 disease from the new virus variant first identified there, known as B.1.351.

The study has not yet been peer reviewed or published in full, so many unknowns remain. What we do know is that it included a relatively small number of volunteers who were predominantly young and healthy and therefore not likely to suffer from severe Covid-19 disease.

08.02.2021 - 16:34 [ Reuters ]

New COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy

(20.01.2021)

“This lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies,” the team of scientists from three South African universities working with the National Institute for Communicable Diseases (NICD) wrote in a paper in bioRxiv, a website that publishes scientific research prior to its being peer-reviewed and submitted to journals.